Why Intratumoral Immunotherapy Still Works—Even Without PD-L1

Описание: Why Intratumoral Immunotherapy Still Works—Even Without PD-L1

“Heard your tumor doesn’t express PD-L1? That doesn’t mean immunotherapy won’t work.”

In this episode of the Prescribed Podcast, Dr. Nathan Goodyear and Dr. Jason Williams explain why intratumoral immunotherapy is far more advanced than single-agent PD-1 treatments:

• PD-L1 isn’t even a reliable marker

• Williams Cancer Institute uses multi-checkpoint strategies: LAG-3, B7-H3, OX40, 4-1BB, CD40 & more

• This is a next-generation immunotherapy approach—precise, layered, and powerfully effective

Forget the outdated thinking. The future of cancer care is already here.

🎥 Watch the full episode of Prescribed on YouTube now.

#IntratumoralImmunotherapy #CancerBreakthrough #PDL1 #Ivermectin #DrNathanGoodyear #DrJasonWilliams #WilliamsCancerInstitute #PrescribedPodcast #CancerInnovation #ImmuneActivation #IntegrativeOncology #CheckpointInhibitors #NextGenCancerCare #HealingJourney #HopeForHealing